PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search
BNF Chapter
BNF Paragraph
Please select a BNF Chapter.
Search Results : Parkinson's disease (Orphenadrine hydrochloride - Parkinson's disease)
Records returned : 27 (on 05 Dec 2024 at 00:24:53). Return to search results for ' Parkinson's disease '.
Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.09.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Blue
Formulations :
- Capsules
- Capsules (slow release)
- Dispersible tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Blue
Formulations :
- Tablets
- Tablets (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Blue
Formulations :
- Capsules
ASPH
RSFT
SASH
SABP
Primary Care
Important
2nd line COMT inhibitor.
Entacapone is the locally agreed 1st-line choice
04.09.01
Blue
Formulations :
- Capsules
- Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Blue
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Blue
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Blue
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.08.01
04.08.02
Blue
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Rapid eye movement disorder
04.01.01
Blue
Formulations :
- Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Rapid eye movement disorder.
Generic 2mg MR tablets.
04.09.01
Blue
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Blue
Formulations :
- Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Blue
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Blue
Formulations :
- Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Blue
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
Preferred COMT inhibitor
04.09.01
Blue
Formulations :
- Patches
ASPH
RSFT
SASH
SABP
Primary Care
Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
04.09.01
Amber
Formulations :
- Pre-filled syringe
- Subcutaneous injection (sc)
- Subcutaneous infusion
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Amber
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Red
Formulations :
- Intestinal gel
ASPH
RSFT
SASH
SABP
Primary Care
06.07.01
Red
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not a 1st-line treatment option.
On-going toxicity monitoring required
04.09.01
06.07.01
Red
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not a 1st-line treatment option.
On-going toxicity monitoring required
04.09.01
Red
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Not a 1st-line treatment option.
On-going toxicity monitoring required
N/A
Formulations :
- Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
N/A
Formulations :
- Intestinal gel
ASPH
RSFT
SASH
SABP
Primary Care
04.09.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
04.09.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
04.09.01
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
For information about the icons and status values within this site, please refer to the keys below.
Icon/Links Key
NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE
Traffic Light Status Key
Red
Amber
Green
Black
Amber Star
Green (see narrative)
Non Formulary
See Below
N/A
Blue
Green - Black
See narrative
Do not initiate in new patients